Raj Bhatia, MD
Critical Care Medicine · Oxnard, CANPI 1447281704
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,690 of the $2,200 with a category attached, or 76.8%. It is spread thinly across 21 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations.
Across 58 payments — averaging $37.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$356
- GSK$347
- Jazz Pharmaceuticals Inc.$236
- Actelion Pharmaceuticals US, Inc.$190
- AstraZeneca$178
- Insmed, Inc.$165
- plus $727 from 15 others
Across 37 payments — averaging $2567.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$95K
What the payments were for
- Food & beverage$1,69077%
- Education$25011%
- Gifts$26012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 3 | $356 |
| GSK | 12 | $347 |
| Jazz Pharmaceuticals Inc. | 4 | $236 |
| Actelion Pharmaceuticals US, Inc. | 4 | $190 |
| AstraZeneca | 4 | $178 |
| Insmed, Inc. | 8 | $165 |
| Harmony Biosciences LLC | 4 | $164 |
| Inspire Medical Systems, Inc. | 2 | $160 |
| Medical Graphics Corporation | 1 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $54 |
| Lilly USA, LLC | 2 | $49 |
| Philips North America LLC | 2 | $43 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $40 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Baxter Healthcare | 1 | $25 |
| United Therapeutics Corporation | 1 | $24 |
| Livanova USA, Inc. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $16 |
| Pfizer | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,200 in reported general payments places this provider in the 75th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 16 | $109,724 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $85,540 |
| Ambrisentan | 11 | $73,300 |
| Breo ElliptaFluticasone/Vilanterol | 105 | $53,296 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $17,582 |
| SunosiSolriamfetol Hcl | 12 | $16,844 |
| Spiriva RespimatTiotropium Bromide | 24 | $15,187 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $12,254 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,212 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,828 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $2,568 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 74 | $2,332 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $1,694 |
| Modafinil | 20 | $1,456 |
| Eszopiclone | 21 | $752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $347 | $138,836189 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $178 | $22,41047 claims |
| Axsome Therapeutics, Inc.Sunosi | $39 | $16,84412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Oxnard
- Brian ShermanOxnard$147K
- Cedric Franklin RutlandRiverside$3.2M
- Chinh PhanSacramento$467K
- Timothy AlbertsonSacramento$418K
- Stephen ChenMonterey Park$394K
- Bassam YaghmourOrange$376K
- Xuanha WhiteSan Diego$343K
- Ken YonedaSacramento$173K
- Praveen AkuthotaSan Diego$169K
- Ivan ChengSan Francisco$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.